| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 24.2 | 21.2 |
| Gross profit | 18.5 | 16.5 |
| Profit before tax | 8.7 | 7.3 |
| Net income | 6.5 | 5.6 |
| EPS (diluted, $ a share) | $0.51 | $0.43 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +16.7% |
|---|---|
| Revenue, year on year | +14.2% |
| Gross margin | 76.3% |
| Operating margin | 33.6% |
10-Q filed with the SEC, NASDAQ: IRMD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Iradimed Corp: key numbers
- Share price
- $84.84Close, Nov 16
- Market cap
- $1.08B
- Shares outstanding
- 12.79MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Iradimed Corp
All →Iradimed Earnings Call: Key Takeaways
Iradimed delivered record Q3 revenue driven by the 3870 pump launch, though management lowered the top-end of full-year revenue guidance due to production ramp constraints.
- Call
- Oct 30, 2026, 11:00 AM ET
Iradimed Financial Results
IRADIMED reported record Q3 2026 revenue of $24.2 million, a 14% year-over-year increase driven by the launch of its new 3870 MR IV pump. The company also declared a quarterly cash dividend of $0.20 per share and updated its full-year 2026 revenue guidance to a range of $91.6 million to $93.1 million.
- Term
- Q3 2026
“We are pleased to report record revenue of $24.2 million for the third quarter, driven by the continued successful launch of our new 3870 MR IV pump. As our manufacturing team gains experience with the new platform while at the same time greatly ramping up production, we began realizing the efficiencies we anticipated with gross margin improving sequentially as expected.”
Roger Susi, President and Chief Executive Officer of Iradimed
“For the fourth quarter of 2026, we expect revenue of $25.0 million to $26.5 million, attaining a $100.0 million revenue run rate while generating GAAP diluted earnings per share of $0.53 to $0.57 and non-GAAP diluted earnings per share of $0.57 to $0.61.”
Roger Susi, President and Chief Executive Officer of Iradimed